Analysis of the rationality of Kanglaite injection in clinical application

Zhuang Xingxing; Ren Jiaxiu; Gao Wenchao; Ni Shoudong

doi:10.3760/j.issn.1673-4777.2025.08.024

Abstract：Objective To evaluate and analyze the rationality of clinical application of Kanglaite injection,in order to provide reference for the rational use of Kanglaite injection.Methods From the electronic medical record system of Chaohu Hospital of Anhui Medical University,120 medical records using Kanglaite injection from January to April(before the special review)and 120 medical records from September to December 2023(after the special review)were randomly selected for retrospective analysis.The gender,age,clinical department,clinical diagnosis,treatment course,usage and dosage of the patients were statistically analyzed,the use rule was analyzed,and the rationality of clinical use was evaluated.The rationality data of the drug application before and after the special review were compared.Results Before the special review,the oncology department had the highest number of 120 hospitalized patients who received Kanglaite injection,with 77 cases(64.2％),followed by the respiratory department with 41 cases(34.2％);non-small cell lung cancer was the most commonly diagnosed disease(77 cases,accounting for 64.2％),followed by primary liver cancer(10 cases,accounting for 8.3％).The indications for use were consistent with the drug instructions.The route of administration of Kanglaite injection was intravenous drip,and the frequency of administration was once a day,which was in line with the recommendation of the instructions.There were 108 cases(90.0％)with a single dose of 200 ml,which met the recommendation of the manufacturer's instructions.Four patients(3.3％)had abnormal fat metabolism,which was a contraindication.The proportion of off-label use without indications in 120 patients after the special review was significantly lower than that before the special review,and the proportion of reasonable medication course was significantly higher than that before the special review[13.3％(16/120)vs 27.5％(33/120),25.0％(30/120)vs 1.7％(2/120)](both P＜0.05).No contraindications were found after the special review.Conclusions There are some unreasonable phenomena in the clinical use of Kanglaite injection,mainly manifested as off-label indication,short course of medication,and small single dose.Clinicians should strictly follow the drug instructions and relevant guidelines to improve the rationality of clinical use of Kanglaite injection.